ArticleScientific reports2025
Explainable machine learning identifies immune-inflammatory biomarkers and therapeutic candidates in drug-resistant epilepsy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MarkerScout: A Disease-Agnostic Machine Learning Framework for Biomarker Prediction from Multi-Scale Mechanistic Models.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant epilepsy (DRE) affects one-third of total epileptic patients and remains a major clinical challenge. Growing evidence implicates neuroinflammation as a key contributor to epileptogenesis and therapeutic resistance, but comprehensive, reproducible transcriptomic biomarkers are lacking. This study aimed to identify immune-inflammatory gene signatures associated with DRE using integrated transcriptomic profiling and machine-learning classifiers coupled with SHAP-based post-hoc explainability. Herein, this study curated and integrated 197 publicly available RNA-sequencing samples from cortical and hippocampal tissues across three Gene Expression Omnibus (GEO) datasets, comprising 162 epileptic and 35 non-epileptic control samples. After preprocessing and batch correction, differential expression analysis and ensemble-based feature selection were performed using the supervised classifiers Logistic Regression (LR), Random Forest (RF), Support Vector Machine (SVM), Extra Trees (ETs), and XGBoost. SHAP (SHapley Additive Explanations) values were used to prioritize features. External validation was conducted on an independent dataset (n = 68). Drug-gene interactions and molecular docking were applied to top-ranked genes. A set of 897 differentially expressed genes (DEGs), including 659 upregulated and 238 downregulated genes, was identified and was enriched for immune-inflammatory processes. Machine learning classifiers achieved high internal performance (mean ROC-AUC: 0.98-0.99) and robust external validation (ensemble ROC-AUC: 0.93). SHAP analysis consistently prioritized genes, including TNF, IL1B, and P2RY12. These features were biologically enriched in microglial and monocyte-related pathways. Drug-gene interaction identified multiple repurposable compounds, with Prasugrel and Pentamidine having strong binding affinities in docking studies. This study reveals reproducible immune-related transcriptomic biomarkers of drug-resistant epilepsy, highlights actionable targets for therapeutic repurposing, and provides a framework for precision medicine approaches in epilepsy. Code and processed data are available at: https://github.com/Tayyab-Ijaz/EpilepsyBiomarkerDrugs .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.